- Early Bird
- Posts
- AbbVie Top Investing Plan 2025 📊
AbbVie Top Investing Plan 2025 📊
A good pick or avoid the stock?
Early Bird Prime for June 15, 2025
In 2025, AbbVie $ABBV ( â–¼ 0.7% ) , the pharmaceutical giant, has been the talk of the town. After a strong start to the year, the company has hit a few speed bumps, leaving investors scratching their heads and wondering if they should jump on the AbbVie bandwagon or stay away. With a 6.49% increase this year, AbbVie is outperforming the overall market.
AbbVie kicked off 2025 with a bang, thanks to its robust immunology portfolio, favorable regulatory news, and good financial results. But AbbVie has recently faced some turbulence. Tariff concerns, slowing demand in the aesthetics business, and valuation worries have caused the stock to stumble.
Enter Mohit Bansal, the analyst from Wells Fargo who seems to have a crystal ball. This week, Bansal maintained a Buy rating on AbbVie and kept the price target at $240.00.
Bansal's continued support for AbbVie isn't just based on a hunch. The company's blockbuster immunology drugs, Skyrizi and Rinvoq, have been performing like rock stars on a world tour, bringing in strong growth.
Still, there are concerns about AbbVie’s prospects.
Should you buy AbbVie's stock now in 2025 or avoid the stock? Here’s the answer:
Subscribe to Early Bird Prime to read the rest.
Become a paying subscriber of Early Bird Prime to get access to this post and other subscriber-only content.
Already a paying subscriber? Sign In.
A subscription gets you:
- • Expert analysis on the best stocks.
- • Stock price predictions based on machine learning.
- • Investing picks and recommendations.
- • Advertisement-free.